Introduction
Polysubstance use (PSU), the simultaneous or concurrent use of two or more psychoactive substances has become the most common form of chronic substance use today in the developed world. Most alcohol dependent individuals are also chronic consumers of tobacco products, many cocaine and/or amphetamine dependent individuals also smoke cigarettes and consume alcohol regularly, and many of these substance users also smoke marijuana (cannabis) [1,2 ,3] . Monosubstance use appears to be a thing of the past, except perhaps for nicotine dependence and when substance use is first initiated. This is reflected in the changing profile of the clientele at substance abuse treatment centers in the developed world, where the majority of individuals with alcohol use disorders, for example, also chronically misuse illicit drugs.
Research aimed at understanding the effects and correlates of substance use on the brain has traditionally focused on studying the substance of interest by excluding or minimizing the concurrent use of other substances. Although this valid scientific approach has provided invaluable insights into the neural correlates of individual substances misused, it also raises questions about generalizability: How relevant are these findings to today's substance users? Can these insights inform properly on brain changes related to PSU so that they can intelligently inform the design and development of effective treatment for PSU?
The current knowledge of brain structural alterations in polysubstance users is very limited, and we dare say that this contributes not only to a lack of understanding of the functional ramifications of such alterations, but more importantly also to the lack of effective treatment and the lack of guidance for clinical management of the majority of individuals seen in treatment today. Here, we first give a brief summary of brain structural alterations described for different classes of abused substances and then review the limited literature on brain structural alterations associated with PSU. Throughout the narrative, we highlight brain morphometric differences between monosubstance and polysubstance users, which we believe are reason for targeted treatment approaches based on the class of substances abused.
Monosubstance use studies by name
Brain tissue loss with concomitant cerebral spinal fluid enlargements is well established in alcohol use disorders (AUD) (for recent reviews see e.g., [4, 5 ] ). Quantitative structural magnetic resonance imaging (MRI) in chronic alcohol users showed that the gray matter regions primarily reduced are the bilateral prefrontal cortices, the posterior cingulate cortex, the insula, and subcortical brain regions, including the bilateral dorsal striatum (caudate, putamen, and nucleus accumbens), the hippocampi, and the amygdala; additional periventricular white matter loss is a common finding in severe alcohol users [6] . By enlarge, these are brain regions commonly described as abnormal in the general drug addiction literature, and most belong to a neural network referred to as the brain reward/executive oversight system (BREOS), which enables cognition, adaptive and appropriate goal-related behavior including reward and affect. Because the prefrontal brain is involved in drug-craving, impulsive/compulsive behavior and decision-making, its 
